Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have been given a consensus rating of “Buy” by the six analysts that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $3.56.

A number of analysts have weighed in on IDXG shares. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Interpace Diagnostics Group in a report on Wednesday, February 20th. Maxim Group reaffirmed a “buy” rating and issued a $4.00 target price on shares of Interpace Diagnostics Group in a report on Wednesday, March 20th.

IDXG stock traded down $0.01 during midday trading on Friday, reaching $0.71. 300 shares of the company were exchanged, compared to its average volume of 275,298. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 0.05. Interpace Diagnostics Group has a 1-year low of $0.67 and a 1-year high of $1.78. The stock has a market cap of $26.67 million, a P/E ratio of -1.64 and a beta of 2.28.

Interpace Diagnostics Group (NASDAQ:IDXG) last released its quarterly earnings data on Monday, May 13th. The business services provider reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). Interpace Diagnostics Group had a negative return on equity of 34.69% and a negative net margin of 53.75%. The company had revenue of $6.01 million for the quarter, compared to analyst estimates of $6.10 million. On average, equities research analysts predict that Interpace Diagnostics Group will post -0.25 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the company. Northern Trust Corp increased its holdings in shares of Interpace Diagnostics Group by 27.4% in the 1st quarter. Northern Trust Corp now owns 88,246 shares of the business services provider’s stock valued at $70,000 after acquiring an additional 19,001 shares during the period. Virtu Financial LLC increased its holdings in shares of Interpace Diagnostics Group by 18.4% in the 4th quarter. Virtu Financial LLC now owns 89,036 shares of the business services provider’s stock valued at $71,000 after acquiring an additional 13,846 shares during the period. Essex Investment Management Co. LLC increased its holdings in shares of Interpace Diagnostics Group by 12.4% in the 4th quarter. Essex Investment Management Co. LLC now owns 339,678 shares of the business services provider’s stock valued at $272,000 after acquiring an additional 37,506 shares during the period. Sio Capital Management LLC acquired a new position in shares of Interpace Diagnostics Group in the 1st quarter valued at $1,322,000. Finally, Perkins Capital Management Inc. increased its holdings in shares of Interpace Diagnostics Group by 86.4% in the 1st quarter. Perkins Capital Management Inc. now owns 1,922,250 shares of the business services provider’s stock valued at $1,538,000 after acquiring an additional 891,250 shares during the period. 22.81% of the stock is currently owned by institutional investors and hedge funds.

About Interpace Diagnostics Group

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.